CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

CJC-1295 vs GHRP-2, GHRP-6 and Hexarelin Compared

Real Peptides Research TeamEditorial

Updated September 28, 20269 min read

43 WORDS

Short answer

Most people searching CJC-1295 vs GHRP-2 assume they're choosing a winner. In the published research these two compounds are rarely competitors, because they bind different receptors on the same pituitary cell and are studied in combination far more often than against each other.

Key takeaways

CJC-1295 is a GHRH receptor analog while GHRP-2, GHRP-6 and hexarelin are ghrelin mimetics at GHS-R1a, so they act through entirely separate receptor pathways.
CJC-1295 with DAC carries an albumin-binding linker giving it a circulating life measured in days, while the no-DAC form clears in roughly half an hour.
GHRP-6 is the hexapeptide most associated with appetite stimulation, and hexarelin with the strongest cortisol and prolactin cross-activation.
Ipamorelin is a five-amino-acid selective GHS-R1a agonist reported to release growth hormone with minimal ACTH, cortisol or prolactin response.
Hexarelin shows attenuation of the GH response over continued exposure, which is the main reason its acute potency advantage narrows in longer research models.
Net peptide content on a certificate of analysis is not the same figure as vial fill weight, and confusing the two is a leading source of unexplained variance between labs.

Our team fields this comparison constantly from lab buyers evaluating secretagogue classes, and the confusion is almost always identical: the search treats a GHRH analog and a ghrelin mimetic as two flavours of the same thing. They aren't. Getting that distinction right changes how a study is designed and which vial belongs in the freezer.

What is the difference between CJC-1295 and GHRP-2?

CJC-1295 vs GHRP-2 compares two different compound classes, not two versions of one. CJC-1295 is a growth hormone releasing hormone (GHRH) analog that binds the GHRH receptor on somatotroph cells. GHRP-2 is a synthetic hexapeptide ghrelin mimetic that binds GHS-R1a, a separate receptor. Research models frequently pair them because the two pathways amplify each other.

One oversimplification distorts almost every forum thread on this topic: CJC-1295 is not a single compound. The version with DAC (Drug Affinity Complex) carries an albumin-binding linker that extends its circulating life to roughly a week, while the no-DAC form, also called modified GRF(1-29), clears in about half an hour. That difference matters more to a study design than any GHRP-2 vs CJC-1295 potency argument. What follows covers the receptor mechanisms, where GHRP-6 and hexarelin diverge from GHRP-2, and what a research buyer should check on a certificate of analysis before ordering either class.

Two receptors, one axis

CJC-1295 and the GHRPs enter the growth hormone axis through separate doors. CJC-1295 is built on the first 29 amino acids of native GHRH with four substitutions that resist degradation by dipeptidyl peptidase-4 (DPP-4), the enzyme that chews up native GHRH within minutes. It binds the GHRH receptor and, in the literature, increases the amplitude of the growth hormone pulses the pituitary was already generating. It works with the body's existing rhythm rather than overriding it.

GHRP-2 (also known as pralmorelin, which is used in Japan as a diagnostic agent for growth hormone deficiency), GHRP-6 and hexarelin are synthetic hexapeptides, six amino acids each. None of them touch the GHRH receptor. All three act at GHS-R1a, the growth hormone secretagogue receptor that native ghrelin occupies, and research describes a dual action: direct stimulation of GH release plus functional suppression of somatostatin, the inhibitory brake on the pituitary.

That is why the framing of CJC-1295 vs GHRP-2 misses the point in most protocols. Work going back to Bowers' GHRH/GHRP co-administration studies reports a combined response greater than either agent produces alone, because releasing the brake and pressing the accelerator are separate actions. We see this reflected in what labs actually order: paired, not either-or.

Why the ghrelin mimetics are not interchangeable

The three GHRPs share a receptor but not a side-effect profile, and that is where most comparisons go wrong. GHRP-6 is the one consistently associated in research with marked appetite stimulation, a ghrelin-receptor effect that becomes a confound in any study measuring food intake or body composition. So GHRP-6 vs CJC-1295 is not a potency question at all, it is a question of whether an appetite variable belongs in the model. GHRP-2 produces less of that effect but is reported to raise cortisol and prolactin to a modest degree. Hexarelin, the most potent GH releaser of the three in acute studies, carries the strongest reported cortisol and prolactin cross-activation, and it also binds CD36, a scavenger receptor expressed in cardiac tissue, which is why hexarelin appears in cardiovascular literature that never mentions the other GHRPs.

Here's the detail most comparison pages skip. Hexarelin is the GHRP most associated in the literature with attenuation of the GH response over continued exposure, an apparent receptor desensitisation effect. That single characteristic reshapes hexarelin vs CJC-1295 study design: the GHRH analog's response tends to hold across repeated exposure, while hexarelin's acute advantage may narrow. When researchers weigh hexarelin vs CJC-1295 vs ipamorelin, ipamorelin usually wins on cleanliness, not power. It is a pentapeptide, five amino acids, reported by Raun and colleagues in the European Journal of Endocrinology to release GH with minimal ACTH, cortisol or prolactin response.

What actually separates one vial from another

Receptor pharmacology is settled science. Vial contents are not. Two labs comparing GHRP-2 vs CJC-1295 with material from different suppliers can produce results that diverge for reasons that have nothing to do with the molecules, because purity, peptide content and correct sequencing vary enormously across the research supply chain.

A legitimate certificate of analysis should show HPLC purity, mass spectrometry confirming the expected molecular weight, and net peptide content, which is not the same number as vial fill weight. A lyophilised powder contains counterions and residual moisture, so a 10mg vial does not necessarily contain 10mg of peptide. That gap is the single most common source of unexplained variance we see reported back to us.

Handling is equally unglamorous and equally decisive. Lyophilised peptides are stored at around -20°C; once reconstituted, solutions are held at 2°C to 8°C and protected from light and repeated freeze-thaw cycles, since each cycle risks aggregation and loss of active material. This is why every batch we synthesise is small-batch with published certificates of analysis, and why our CJC-1295 No DAC 10mg ships with the same documentation as every other sequence in the catalogue. These compounds are supplied strictly for laboratory research and are not FDA-approved drugs for human or veterinary use. Anyone with a question about an animal's health should speak with a licensed veterinarian rather than source a research peptide.

Side-by-side: CJC-1295 vs GHRP-2, GHRP-6 and hexarelin

This table sets out what actually differentiates the compounds in a research setting: receptor class, reported duration, and the selectivity issues that decide whether a peptide fits a given model.

Compound	Receptor class	Reported duration	Selectivity notes	Common research context	Bottom line
CJC-1295 with DAC	GHRH receptor analog	Extended, roughly a week, via albumin binding	Does not cross-activate ghrelin pathways	Studies needing sustained GHRH receptor occupancy	Longest-acting option, but continuous occupancy flattens the natural pulse pattern researchers often want to preserve
CJC-1295 no DAC (mod GRF 1-29)	GHRH receptor analog	Short, on the order of half an hour	No reported cortisol or prolactin cross-activation	Pulse-fidelity models and GHRH/GHRP co-administration	The cleaner GHRH arm when the study question is pulse shape rather than total exposure
GHRP-2 (pralmorelin)	GHS-R1a ghrelin mimetic	Short, tens of minutes	Modest reported cortisol and prolactin elevation	Diagnostic GH stimulation work; paired secretagogue models	The most balanced hexapeptide, which is why GHRP-2 vs CJC-1295 usually resolves into pairing them
GHRP-6	GHS-R1a ghrelin mimetic	Short, tens of minutes	Pronounced appetite stimulation reported	Ghrelin signalling and feeding-behaviour research	Only choose it if appetite signalling is the variable being studied, not an accident
Hexarelin	GHS-R1a plus CD36 binding	Short, tens of minutes	Highest reported cortisol and prolactin cross-activation; desensitisation over repeated exposure	Acute GH release and cardiac CD36 research	Most potent acutely, least durable, and the hardest to isolate cleanly in a controlled design
Ipamorelin	Selective GHS-R1a agonist	Short, tens of minutes	Minimal reported ACTH, cortisol or prolactin response	Selectivity-sensitive models and GHRH pairings	The low-noise ghrelin mimetic when confounding hormone release would wreck the data

What If: common research scenarios

What if a protocol calls for both a GHRH analog and a ghrelin mimetic?

That is the standard arrangement in the co-administration literature rather than an exception. GHRH analogs and GHS-R1a agonists act on different receptors and the reported combined GH response exceeds either compound alone, which is why prepared pairings such as CJC-1295 with Ipamorelin exist as a single research item. The design question is which ghrelin mimetic keeps confounding hormones out of the data.

What if the vial looks different from the last batch?

Stop and check the certificate of analysis before reconstituting anything. Lyophilised peptide cake appearance varies legitimately with fill volume, lyophilisation cycle and vial geometry, so a flatter or more fragmented cake is not automatically a quality failure. A cake that has collapsed into a sticky film, or shows discolouration, usually points to moisture ingress or a temperature excursion, and neither is reversible.

What if the GH response fades across repeated exposures in a model?

Record it as data rather than treating it as a material failure. Receptor desensitisation at GHS-R1a is a documented phenomenon with the ghrelin mimetics and is reported most prominently with hexarelin. Verifying compound integrity through the supplier's HPLC and mass spectrometry results separates a genuine pharmacological effect from a degraded vial, which is exactly why batch-level documentation matters.

The plain truth about potency comparisons

Here's the honest answer: ranking CJC-1295 vs GHRP-2 by potency is a category error, and most of the content arguing about it was written by people who never looked at the receptor. A GHRH analog and a ghrelin mimetic are not on the same scale. Hexarelin outperforms GHRP-2 acutely and then desensitises. GHRP-6 stimulates appetite hard enough to contaminate body-composition data. None of that makes any of them better, it makes them appropriate for different questions. Choose the compound that isolates your variable, then choose a supplier that can document what is actually in the vial.

If your work extends across the secretagogue class, our catalogue lists GHRP-2, GHRP-6, hexarelin and ipamorelin alongside the Tesamorelin and Ipamorelin stack, with the full research peptide range documented the same way.

The most useful reframe for anyone researching CJC-1295 vs GHRP-2 is to stop reading it as a versus question. The GH axis has an accelerator and a brake, and these two compound classes operate on different ones. Once that clicks, the real decisions become narrower and far more answerable: DAC or no DAC, which ghrelin mimetic carries the least hormonal noise for your endpoint, and whether the certificate of analysis in front of you actually reports net peptide content. Those three answers will shape a study far more than any potency league table ever could.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

CJC-1295 is a growth hormone releasing hormone analog based on GHRH(1-29) that binds the GHRH receptor on pituitary somatotroph cells. GHRP-2 is a synthetic six-amino-acid ghrelin mimetic that binds GHS-R1a, a completely separate receptor, and also blunts somatostatin signalling. Because they act on different receptors, research models commonly study them in combination rather than as alternatives.

Hexarelin is reported as the most potent acute growth hormone releaser among the common GHRPs, but that comparison is not like-for-like because hexarelin works through GHS-R1a while CJC-1295 works through the GHRH receptor. Research also describes attenuation of hexarelin's GH response across continued exposure, alongside the strongest cortisol and prolactin cross-activation of the group. In hexarelin vs CJC-1295 study design, acute potency and durability point in opposite directions.

GHRP-6 is the ghrelin mimetic most associated in the literature with pronounced appetite stimulation, a direct consequence of agonism at the ghrelin receptor. CJC-1295 acts on the GHRH receptor and is not associated with that appetite effect. For any model measuring food intake or body composition, GHRP-6 introduces a variable that CJC-1295 does not.

CJC-1295 with DAC carries a Drug Affinity Complex, an albumin-binding linker that extends its circulating presence to roughly a week. CJC-1295 no DAC, often labelled modified GRF(1-29), lacks that linker and clears in around half an hour. The practical research consequence is pulse shape: the no-DAC form leaves the natural pulsatile pattern largely intact, while sustained receptor occupancy with the DAC version does not.

Ipamorelin is a selective five-amino-acid GHS-R1a agonist reported by Raun and colleagues in the European Journal of Endocrinology to release growth hormone with minimal ACTH, cortisol or prolactin response. GHRP-2 produces a modest cortisol and prolactin elevation by comparison. When a study endpoint could be confounded by stress hormone release, the cleaner selectivity profile of ipamorelin is the reason for the substitution.

These compounds are sold as research chemicals for in-vitro and laboratory investigation by qualified researchers and institutions. They are not FDA-approved drugs and are not supplied for human or veterinary administration. Purchasers are responsible for compliance with the regulations that apply in their own jurisdiction and institution.

Pricing varies widely by sequence complexity, vial size, synthesis batch size and the level of analytical documentation provided. Longer and more heavily modified sequences such as CJC-1295 with DAC generally cost more to synthesise than a six-amino-acid hexapeptide like GHRP-2 or GHRP-6. The more useful comparison is cost per verified milligram of net peptide content rather than the headline price per vial.

The three practical risks are moisture ingress, temperature excursion and repeated freeze-thaw cycling of reconstituted solution. Lyophilised material is typically stored near -20°C and reconstituted solution held at 2°C to 8°C, protected from light. Degradation by aggregation is not reliably visible to the eye, which is why analytical documentation from the supplier carries more weight than vial appearance.

None of these compounds is an FDA-approved drug product in the United States. GHRP-2 under the name pralmorelin has been used in Japan as a diagnostic agent for growth hormone deficiency, which is a separate regulatory context. Everything supplied by Real Peptides is research-use-only material and is never provided for human or animal consumption.

Hexarelin binds CD36, a scavenger receptor expressed in cardiac tissue, in addition to GHS-R1a. That secondary binding is the reason hexarelin appears in cardiovascular research literature where GHRP-2, GHRP-6 and ipamorelin generally do not. It is also part of why isolating a clean growth hormone endpoint with hexarelin is harder than with a selective agonist.

Net peptide content states how much actual peptide a vial holds, which is lower than the total fill weight because lyophilised material also contains counterions such as trifluoroacetate and residual moisture. A vial labelled 10mg may therefore contain less than 10mg of peptide. Laboratories that calculate from fill weight instead of net peptide content introduce a systematic error into every subsequent measurement.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA